HomeNewsBusinessMarketsTariff pause sets Indian markets up for a roaring rebound on Friday: What should investors do?

Tariff pause sets Indian markets up for a roaring rebound on Friday: What should investors do?

Several market veterans are advicing investors not to be deterred by the volatility and stick to asset allocation, as a host of sectors that had taken the sharpest knock in recent weeks look set to rebound when equity markets open on April 11.

April 10, 2025 / 17:52 IST
Story continues below Advertisement
Nilesh Shah adviced investors to follow asset allocation as per their risk appetite and investment goals. The length of their SIP will define the market returns, he said.
Nilesh Shah adviced investors to follow asset allocation as per their risk appetite and investment goals. The length of their SIP will define the market returns, he said.

US President Trump's 90-day tariff pause spurred global equities on April 10, with GIFT Nifty holding well above 23,100 to indicate a gap up start of nearly 3% as of 5:30pm.

Earlier in the trading session, Asian indices staged a solid recovery, with Nikkei and Taiwan Weighted index closing over 8% higher, and leading European indices DAX, CAC 40 and FTSE rising between 4-6%. On April 9, Trump's tariff pause had sparked a massive rally in US indices, with the S&P 500 recording its biggest rise since 2008.

Story continues below Advertisement

Several market veterans are advicing investors not to be deterred by the volatility and stick to asset allocation, as a host of sectors that had taken the sharpest knock in recent weeks look set to rebound when equity markets open on April 11. N Jayakumar, MD at Prime Securities, during a panel discussion on CNBC Awaaz said it will be difficult to catch such gap ups, which are becoming challenging to predict, in present times. He said India's export plays are likely to emerge as beneficiaries over the medium term. "In this China-US standoff, India's exports will take off, as we see new trade blocs emerge, given the trust deficit with US President Trump," Jayakumar added.

Pharma sector is an opportunity to buy for Jayakumar, who said that Trump's threat of tariff on drug makers is more aimed at the Big Pharma based out of Europe, and the dumping into US by China. India's generic manufacturers are largely going be escape unscathed from any levy on pharma, given that the American public may end up bearing the brunt of a potential rise in prices of medicines, said Jayakumar.